3.45
price down icon5.74%   -0.21
pre-market  Pre-market:  3.55   0.10   +2.90%
loading
Terns Pharmaceuticals Inc stock is traded at $3.45, with a volume of 812.06K. It is down -5.74% in the last 24 hours and down -15.44% over the past month. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
See More
Previous Close:
$3.66
Open:
$3.65
24h Volume:
812.06K
Relative Volume:
0.62
Market Cap:
$293.04M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-2.6136
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
-4.96%
1M Performance:
-15.44%
6M Performance:
-61.47%
1Y Performance:
-51.27%
1-Day Range:
Value
$3.435
$3.70
1-Week Range:
Value
$3.24
$3.70
52-Week Range:
Value
$3.24
$11.40

Terns Pharmaceuticals Inc Stock (TERN) Company Profile

Name
Name
Terns Pharmaceuticals Inc
Name
Phone
650-525-5535 EXT.101
Name
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Name
Employee
66
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TERN's Discussions on Twitter

Compare TERN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TERN
Terns Pharmaceuticals Inc
3.45 293.04M 0 -95.90M -79.09M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Mkt Perform
Oct-31-24 Initiated Oppenheimer Outperform
Jun-22-23 Initiated Mizuho Buy
Jun-07-23 Initiated Jefferies Buy
May-31-23 Initiated ROTH MKM Buy
May-08-23 Initiated BMO Capital Markets Outperform
Feb-14-23 Initiated JMP Securities Mkt Outperform
Feb-07-23 Initiated UBS Buy
Sep-12-22 Initiated H.C. Wainwright Neutral
Sep-14-21 Resumed Goldman Buy
Mar-02-21 Initiated Cowen Outperform
Mar-02-21 Initiated Goldman Buy
Mar-02-21 Initiated JP Morgan Overweight
View All

Terns Pharmaceuticals Inc Stock (TERN) Latest News

pulisher
Mar 12, 2025

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Terns Pharmaceuticals stock hits 52-week low at $3.27 - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Terns Pharmaceuticals stock hits 52-week low at $3.27 By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 09, 2025

This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street - sharewise

Mar 09, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 13,479 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

3 Growth Stocks with Exciting Potential - The Globe and Mail

Mar 07, 2025
pulisher
Mar 07, 2025

Chronic Myeloid Leukemia Market Expected to Experience Major - openPR

Mar 07, 2025
pulisher
Mar 07, 2025

Public market insider buying at Paramount Resources (POU) - The Globe and Mail

Mar 07, 2025
pulisher
Mar 06, 2025

Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

Terns Pharmaceuticals stock hits 52-week low at $3.54 - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Terns Pharmaceuticals stock hits 52-week low at $3.54 By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30 - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

William Blair Initiates Terns Pharmaceuticals at Market Perform -February 28, 2025 at 08:12 am EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

William Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform Recommendation - MSN

Feb 28, 2025
pulisher
Feb 26, 2025

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Terns Pharmaceuticals reports progress in clinical trials By Investing.com - Investing.com Australia

Feb 26, 2025
pulisher
Feb 26, 2025

New Terns Pharmaceuticals CFO Receives $2.8M Stock Option Package: What's Behind the Compensation? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Terns Pharmaceuticals reports progress in clinical trials - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Terns Pharmaceuticals Provides Program Updates and - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th ... - The Bakersfield Californian

Feb 25, 2025
pulisher
Feb 25, 2025

Can Terns Pharmaceuticals' $372M Cash Runway Fuel Its Promising CML and Obesity Pipeline? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Terns Pharmaceuticals Names Andrew Gengos as Chief Financial Officer -February 25, 2025 at 04:55 am EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 24, 2025

Terns Pharmaceuticals appoints Andrew Gengos as CFO - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

Terns Pharmaceuticals Appoints Andrew Gengos as CFO - MSN

Feb 24, 2025
pulisher
Feb 24, 2025

Terns Pharmaceuticals appoints new CFO to bolster growth By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Terns Pharmaceuticals appoints new CFO to bolster growth - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - StockTitan

Feb 24, 2025
pulisher
Feb 22, 2025

Terns Pharmaceuticals stock hits 52-week low at $4 - Investing.com India

Feb 22, 2025
pulisher
Feb 21, 2025

Terns Pharmaceuticals stock hits 52-week low at $4 By Investing.com - Investing.com Nigeria

Feb 21, 2025
pulisher
Feb 21, 2025

Oppenheimer Initiates Coverage of Terns Pharmaceuticals (TERN) with Outperform Recommendation - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

Terns Pharmaceuticals Appoints Robert Azelby to Board - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Can This New Board Addition Transform Terns' Oncology Commercialization Strategy? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Savant Capital LLC Makes New $89,000 Investment in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Feb 20, 2025
pulisher
Feb 15, 2025

Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Terns Pharmaceuticals stock hits 52-week low at $4.16 By Investing.com - Investing.com Canada

Feb 14, 2025
pulisher
Feb 12, 2025

Bleakley Financial Group LLC Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

Terns Pharmaceuticals announces CFO transition and consulting agreement - MSN

Feb 11, 2025

Terns Pharmaceuticals Inc Stock (TERN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):